A wearable health monitor synched with a smart phone app could enable remote detection of early SARS-CoV-2 infection.

Rebecca Bromley-Dulfano, MS, says expanding access to home testing and virtual care is key to closing racial gaps in treatment.

HIV+Hepatitis Policy Institute director discusses PrEP access, insurer compliance, and challenges ahead following the landmark decision.

Invivyd forms the SPEAR Study Group to evaluate pemivibart for Long COVID and post-vaccine syndrome, exploring monoclonal antibody treatment of spike protein.

Six health organizations and a physician challenge the legality of rescinded vaccine recommendations and dismissal of federal advisory members.

Grace Kulik, PT, DPT, discusses key risk factors and the role of inflammation, ART, and screening in preserving mobility among aging individuals with HIV.

The role of oral vancomycin in preventing recurrence of C difficile infection (CDI) in at-risk persons receiving systemic antibiotic for non-CDI infection remains unclear after randomized trial.

This week, Moderna’s mRNA-1010 flu vaccine showed strong phase 3 results, new research reveals that FMT may fail due to functional mismatches between donor microbes and the recipient’s gut, and more.

Significant short-term impact of MDA with dihydroartemisinin–piperaquine plus primaquine in a moderate-to-low transmission setting, highlighting the need for full seasonal coverage and community engagement to sustain gains.

In Part 2, Anna Seekatz, PhD and PhD candidate Sophie Millard highlight the need for precision microbial therapies tailored to host-specific gut environments.

Clemson University researchers Anna Seekatz, PhD, and PhD candidate Sophie Millard uncover how functional mismatches between donor microbes and recipient gut environments could limit the success of microbiome-based therapies.

A multicenter US study confirms that RBL is a safe and effective microbiota-based therapy with sustained remission in a high-risk, comorbid population.

Vaccine candidate demonstrates 26.6% higher relative efficacy in adults 50 and older, with strong protection across flu strains.

Findings from recent studies published in BMC Gastroenterology highlight practical diagnostic tools and novel therapeutic strategies to improve management of chronic hepatitis B.

Centers for Disease Control and Prevention report underscores need for improved surveillance, donor screening, and public awareness as rare WNV strain emerges and Powassan virus cases hit new high.

Several companies nationwide, with FDA oversight, recalled food products due to potential bacterial contamination, issuing consumer warnings to prevent foodborne illness.

Use of an AI-guided infection prevention bundle did not significantly reduce CDI incidence but was associated with increased antimicrobial stewardship.

Results from Invivyd’s pemivibart (Pemgarda) phase 3 trial show it had a significant PrEP effect during the 6-month on-drug period for both immunocompromised and immunocompetent populations.

This week, the ACIP recommends clesrovimab for RSV protection in infants under 8 months without maternal immunity, ASM Microbe talk urges for creative funding solutions amid federal freezes to sustain research and careers, and more.

6–3 ruling preserves no-cost insurance coverage for preventive services such as HIV PrEP, contraceptives, and screenings.

Robert C Bransfield, MD, continues to share how vector-borne infections may trigger psychiatric symptoms not through direct brain infection, but by disrupting immune signaling and gene expression.

Screening for an immunological biomarker in the nasal passage can effectively rule out a respiratory virus — reducing the need for conventional PCR tests.

Johns Hopkins is offering its Pamela Tucker transplant and oncology infectious diseases course. Its director, Shmuel Shoham, MD, offers more information about this continuous education opportunity.

A retrospective study finds no significant difference in treatment failure between patients with obesity and those without.

John Rex, MD, FACP, discusses the promise, precision, and challenges of this first-in-class antifungal following phase 2b trial results.